Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Anisa Mohammed"'
Autor:
Rajeev P. Nagassar, Narin Jalim, Arianne Mitchell, Ashley Harrinanan, Anisa Mohammed, Darren K. Dookeeram, Danini Marin, Lucia Giangreco, Paola Lichtenberger, Gustavo H. Marin
Publikováno v:
Antibiotics, Vol 12, Iss 3, p 466 (2023)
An antimicrobial consumption (AMC) study was performed in Trinidad and Tobago at the Eastern Regional Health Authority (ERHA). A retrospective, cross-sectional survey was conducted from 1 November 2021 to 30 March 2022. Dosage and package types of am
Externí odkaz:
https://doaj.org/article/8aa4112432ea431cb82220308743ca11
Autor:
Kidist Adamu, Amsalu Feleke, Amare Muche, Toyeb Yasin, Asnakew Molla Mekonen, Muluken Genetu Chane, Sisay Eshete, Anisa Mohammed, Abel Endawkie, Zinabu Fentaw
Publikováno v:
PLoS ONE, Vol 17, Iss 9, p e0268150 (2022)
IntroductionHypertension is one global public health emergency disease, and is one of the most critical factors for chronic diseases such as cardiovascular disease, stroke, arrhythmias, heart failure, and renal diseases. Hypertension affects quality
Externí odkaz:
https://doaj.org/article/46baad3558d1421fa4401dcbf72e98c5
Publikováno v:
Volume: 6, Issue: 16 602-616
IJASOS-International E-journal of Advances in Social Sciences
IJASOS-International E-journal of Advances in Social Sciences
This case study aimed to reveal the degree of readiness in the second cycle schools at Wilayat Saham; to implement the Omani Child Law, from the school principals’ perspectives. The problem emerged; that 44.5% of students were assaulted during thei
Autor:
Sun Loo, Rupa Narayan, Mikael L. Rinne, Mika Kontro, Andrew M. Stein, Oliver G. Ottmann, Haiying Sun, Norbert Vey, Jeroen Janssen, Guillermo Garcia-Manero, Steve Knapper, Kimmo Porkka, Sebastian Scholl, Jordi Esteve, Fariba Khanshan, Andrew H. Wei, Elie Traer, Uma Borate, Purushotham Naidu, Natalia Tovar, Martin Wermke, Anisa Mohammed, Na Zhang, Andrew M. Brunner, Siyan Xu, Serena Liao
Publikováno v:
Blood. 136:40-42
Background: Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor expressed on multiple immune cells and on leukemic stem/progenitor cells and blasts, but not on normal hematopoietic stem ce
Autor:
Andrew M. Brunner, Uma Borate, Andrew H. Wei, Mikael L. Rinne, Rupa Narayan, Purushotham Naidu, Oliver G. Ottmann, Steve Knapper, Siyan Xu, Anisa Mohammed, Martin Wermke, Andrew Lewandowski, Sun Loo, Mika Kontro, Elie Traer, Natalia Tovar, Andrew M. Stein, Na Zhang, Haiying Sun, Kimmo Porkka, Norbert Vey, Guillermo Garcia-Manero, Sebastian Scholl, Jeroen Janssen
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S349-S350
Context: Sabatolimab is an investigational immuno-myeloid therapy targeting TIM-3. The STIMULUS clinical trial program has been designed to evaluate sabatolimab in multiple phase 1–3 trials in patients with MDS and AML. Here, we report PK and clini
Autor:
Jordi Esteve, Mikael L. Rinne, Mika Kontro, Sun Loo, Martin Wermke, Elie Traer, Rupa Narayan, Marc Pelletier, Jeroen Janssen, Andrew H. Wei, Natalia Tovar, Kimmo Porkka, Steve Knapper, Guillermo Garcia-Manero, Purushotham Naidu, Na Zhang, May Han, Sebastian Scholl, Andrew M. Brunner, Norbert Vey, Oliver G. Ottmann, Andrew Lewandowski, Uma Borate, Anisa Mohammed
Publikováno v:
Blood. 138:244-244
Background: Pts with higher-risk MDS and AML need treatment options that provide durable responses with sustained clinical benefit and favorable safety/tolerability. Sabatolimab is a novel immuno-myeloid therapy targeting TIM-3, an immune regulator e
Autor:
Norbert Vey, Sebastian Scholl, Anisa Mohammed, Purushotham Naidu, Fei Ma, Uma Borate, Andrew M. Brunner, Nidhi Patei, Mika Kontro, Jeroen Janssen, Elena Orlando, Elie Traer, Martin Wermke, Natalia Tovar, Steve Knapper, Jessica Makofske, Mikael L. Rinne, Oliver G. Ottmann, Rupa Narayan, Andrew H. Wei, Guillermo Garcia-Manero, Sun Loo, Na Zhang, Kimmo Porkka
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S350
Context: Sabatolimab (MBG453) is an investigational immuno-myeloid therapy targeting TIM-3, an immune regulator expressed on immune and myeloid leukemic cells and blasts, but not on normal hematopoietic stem cells. Early phase 1b study (NCT03066648)
Autor:
Guillermo Garcia-Manero, Andrew H. Wei, Kimmo Porkka, Steve Knapper, Norbert Vey, Sebastian Scholl, Martin Wermke, Jeroen Janssen, Elie Traer, Sun Loo, Rupa Narayan, Natalia Tovar, Mika Kontro, Oliver Ottmann, Siyan Xu, Andrew Lewandowski, Andrew Stein, Purushotham Naidu, Na Zhang, Anisa Mohammed, Mikael L. Rinne, Haiying Sun, Andrew M. Brunner, Uma Borate
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S230
Autor:
Guillermo Garcia-Manero, Andrew H. Wei, Kimmo Porkka, Steve Knapper, Elie Traer, Sebastian Scholl, Norbert Vey, Martin Wermke, Jeroen Janssen, Rupa Narayan, Sun Loo, Natalia Tovar, Mika Kontro, Oliver Ottmann, Purushotham Naidu, Elena Orlando, Nidhi Patel, Jessica Makofske, Fei Ma, Na Zhang, Anisa Mohammed, Mikael L. Rinne, Uma Borate, Andrew M. Brunner
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S230
Autor:
Catherine Anne Sabatos-Peyton, Serena Liao, Oliver G. Ottmann, Guillermo Garcia-Manero, Jordi Esteve, Sun Loo, Elie Traer, Natalia Tovar, Anisa Mohammed, Jessica Makofske, Rupa Narayan, Mika Kontro, Uma Borate, Andrew H. Wei, Norbert Vey, Purushotham Naidu, Mikael L. Rinne, Steve Knapper, Sebastian Scholl, Sema Kurtulus, Jeroen Janssen, Kimmo Porkka, Andrew M. Brunner, Martin Wermke
Publikováno v:
Blood. 136:1-2
Background: Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. TIM-3 is expressed on immune cells as well as leukemic stem cells (LSCs